rAAV2tYF-PR.1-hCNGA3 - Applied Genetic Technologies Corporation

Drug Profile

rAAV2tYF-PR.1-hCNGA3 - Applied Genetic Technologies Corporation

Alternative Names: ACHM A3; ACHM CNGA3; AGTC-402; recombinant Adeno-associated virus vector expressing CNGA3

Latest Information Update: 15 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Applied Genetic Technologies Corporation
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Colour vision defects
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Colour vision defects

Most Recent Events

  • 15 Jun 2017 Preclinical trials in Colour vision defects in Israel (Subconjunctival) before June 2017
  • 15 Jun 2017 Preclinical data in Colour vision defects released by Applied Genetic Technologies Corporation
  • 19 Oct 2016 Applied Genetic Technologies Corporation files an IND application with the US FDA for Colour vision defects
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top